CHRNA2 (Cholinergic Receptor Nicotinic Alpha 2) encodes the α2 subunit of the nicotinic acetylcholine receptor (nAChR) family. This ligand-gated ion channel subunit forms heteromeric receptors critical for fast cholinergic synaptic transmission throughout the peripheral and central nervous systems. CHRNA2 has been implicated in epilepsy, autonomic dysfunction, and potentially in neurodegenerative diseases including Alzheimer's Disease and Parkinson's Disease. This page covers the gene's structure, function, disease associations, and therapeutic implications.
| Cholinergic Receptor Nicotinic Alpha 2 |
|---|
| Gene Symbol | CHRNA2 |
| Full Name | Cholinergic receptor nicotinic alpha 2 subunit |
| Chromosome | 8p21 |
| NCBI Gene ID | [1135](https://www.ncbi.nlm.nih.gov/gene/1135) |
| OMIM | [104500](https://www.omim.org/entry/104500) |
| Ensembl ID | ENSG00000120288 |
| UniProt ID | [P43681](https://www.uniprot.org/uniprotkb/P43681) |
| Associated Diseases | [Epilepsy](/diseases/epilepsy), [Autonomic dysfunction](/diseases/autonomic-dysfunction), [AD](/diseases/alzheimers-disease), [PD](/diseases/parkinsons-disease) |
CHRNA2 is a member of the Cys-loop receptor superfamily, which also includes GABAₐ, glycine, and 5-HT₃ receptors. The α2 subunit typically combines with β2 or β4 subunits to form functional heteromeric nAChRs. These receptors are expressed in both the central and peripheral nervous systems, where they mediate fast synaptic transmission and modulate neuronal excitability.
Key characteristics:
- Ligand-gated ion channel (ionotropic receptor)
- Permeable to Na⁺, K⁺, and Ca²⁺
- Activated by acetylcholine (ACh) and nicotine
- Subject to rapid desensitization
The nAChR is a pentameric ligand-gated ion channel. CHRNA2 contributes to the formation of:
- Extracellular N-terminal domain: Contains the acetylcholine binding site
- Transmembrane domain: Four α-helices (M1-M4) forming the ion channel pore
- Intracellular loop: Between M3 and M4, contains phosphorylation sites
- Extracellular C-terminal domain
The ACh binding site is located at the interface between adjacent subunits:
- Principal binding component: C-loop of the α subunit (CHRNA2)
- Complementary component: Adjacent non-α subunit (β2/β4)
Key structural features:
- Aromatic residues (Trp, Tyr, Phe) for ACh binding
- Disulfide bond at the tip of the C-loop (characteristic of Cys-loop receptors)
- Glycosylation sites for proper folding
The channel pore is formed by the M2 transmembrane helices:
- Ring of negatively charged residues at the extracellular entrance (selectivity filter)
- Hydrophobic gate region
- Intracellular entrance with additional regulatory sites
CHRNA2 forms heteromeric nAChRs with specific subunit compositions:
| Receptor |
Stoichiometry |
Expression |
Function |
| α2β2 |
α2:β2 = 2:3 |
CNS, autonomic ganglia |
Major CNS receptor |
| α2β4 |
α2:β4 = 2:3 |
Autonomic ganglia, brain |
Peripheral, some CNS |
| α2α5β2 |
α2:α5:β2 = 1:1:3 |
CNS |
High Ca²⁺ permeability |
The α5 subunit inclusion (α2α5β2) significantly increases Ca²⁺ permeability, which has important implications for neuronal signaling and disease processes.
CHRNA2 demonstrates unique expression patterns:
- Hippocampus: CA1-CA3 pyramidal cells, dentate gyrus granule cells
- Cortex: Layer 2/3 interneurons
- Thalamus: Relay neurons
- Brainstem: Motor and sensory nuclei
- Cerebellum: Molecular layer interneurons
- Autonomic ganglia: Sympathetic and parasympathetic neurons
- Enteric nervous system: Myenteric and submucosal plexus
- Astrocytes (moderate)
- Microglia (low, inducible)
CHRNA2-containing nAChRs mediate:
- Fast excitatory transmission: Direct depolarization via Na⁺ influx
- Presynaptic modulation: Ca²⁺-dependent neurotransmitter release
- Postsynaptic excitation: Integration with other excitatory inputs
The Ca²⁺ permeability of α2β2* and especially α2α5β2 receptors enables:
- Activation of intracellular Ca²⁺ signaling cascades
- Synaptic plasticity mechanisms
- Gene transcription via Ca²⁺-dependent pathways
CHRNA2 receptors modulate:
- Dopaminergic signaling in the striatum
- GABAergic inhibition in cortical circuits
- Glutamatergic transmission
The cholinergic hypothesis of AD proposes that loss of cholinergic neurons contributes to cognitive decline. CHRNA2 is relevant because:
- Presynaptic modulation: α2-containing receptors modulate ACh release
- Attention and memory: nAChR signaling is critical for cognitive function
- Neuroprotection: Nicotinic agonists may protect against Aβ toxicity
- Aβ directly interacts with nAChRs
- Aβ binding may dysregulate α2-containing receptor function
- Nicotinic stimulation may reduce Aβ-induced toxicity
nAChR signaling intersects with tau pathology:
- PKC and CaMKII pathways modulate tau phosphorylation
- Cholinergic dysfunction may exacerbate tau pathology
CHRNA2 receptors influence dopaminergic function:
- Nigrostriatal pathway modulation
- Mesolimbic and mesocortical circuits
- Motor control via basal ganglia circuits
¶ Nicotine and PD
Epidemiological studies show:
- Smoking is associated with reduced PD risk
- Nicotine may protect dopaminergic neurons
- α4/α6-containing receptors (not α2) primarily mediate this effect
CHRNA2 mutations cause autonomic disorders:
- Dysautonomia in epilepsy patients
- Orthostatic hypotension
- Thermoregulatory dysfunction
CHRNA2 mutations cause autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE):
- Phenotype: Brief seizures during sleep
- Mechanism: Gain-of-function mutations increase channel activity
- Treatment: Carbamazepine (Na⁺ channel blocker)
CHRNA2 mutations are associated with:
- Autonomic seizures
- Central hypoventilation
- Cardiac arrhythmias
- Altered nAChR expression in AD brains
- CHRNA2 polymorphism associations with AD risk
- Therapeutic targeting of nAChRs
- nAChR expression changes in PD
- Nicotine protection studies
- CHRNA2 role in autonomic symptoms
- Partial agonists: Varenicline (Chantix®) - smoked cessation
- Positive allosteric modulators (PAMs): Enhance receptor function
- Agonists: Nicotine, cytisine
- Receptor desensitization
- Side effects (nausea, cardiovascular)
- Lack of subtype selectivity
- Subtype-selective agonists
- Brain-penetrant compounds
- Disease-modifying approaches
- Taylor AM, et al. CHRNA2 and neuronal function in CNS (2020): Role of α2-containing nAChRs in neuronal function.
- Hernandez CM, et al. Nicotinic receptors in neurodegenerative disease (2020): nAChRs in AD and PD.
- Courtois V, et al. CHRNA2 mutations in epilepsy (2019): Clinical and functional characterization.